Education
About Us
Working with TipRanks
Follow Us
Poly Medicure Limited (IN:POLYMED)
:POLYMED
POLYMED Stock Chart & Stats
₹1723.55
-₹86.35(-3.04%)
At close: 4:00 PM EST
₹1723.55
-₹86.35(-3.04%)
Day’s Range― - ―
52-Week Range₹1,248.40 - ₹2,936.70
Previous CloseN/A
Volume120.39K
Average Volume (3M)8.86K
Market Cap
₹132.65B
Enterprise Value₹129.42B
Total Cash (Recent Filing)₹12.08B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)38.1
Beta0.94
Next Earnings
May 26, 2026EPS Estimate
9.1Next Dividend Ex-DateN/A
Dividend Yield0.19%
Share Statistics
EPS (TTM)7.70
Shares Outstanding101,359,490
10 Day Avg. Volume7,511
30 Day Avg. Volume8,860
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)7.72
Price to Sales (P/S)12.79
P/FCF Ratio-235.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables PortfolioSingle‑use medical devices generate recurring, hygiene-driven demand and frequent reorder cycles. Poly Medicure’s wide SKU catalog and established hospital/distributor channels support cross‑selling across departments and export markets, creating durable repeat revenue and lowering customer concentration risk.
Consistent Revenue And Improving MarginsConsistent top-line growth with strong gross margins and improving net margins suggests sustained pricing power and effective cost management. This trend implies scalable economics: as volumes grow, operating leverage can strengthen long-term profitability and fund reinvestment in products and market expansion.
Low Leverage And Rising EquityA conservative leverage profile and rising shareholders’ equity provide financial flexibility to invest in capacity, R&D, or geographic expansion without immediate reliance on costly external financing. This balance-sheet strength lowers solvency risk and supports multi-year strategic initiatives.
Bears Say
Negative Free Cash Flow From Heavy CapexSustained negative free cash flow driven by heavy capex reduces internally available funds for dividends, debt reduction, or M&A. If new capacity or investments do not yield timely returns, the company may need external financing, which could raise leverage or constrain strategic flexibility.
EBIT Margin VariabilityFluctuating EBIT margins indicate operating profitability is sensitive to cost, mix, or pricing shifts. This variability undermines earnings predictability and complicates capital allocation and forecasting, increasing execution risk when scaling operations or entering new markets over the medium term.
Rapid Asset Growth, Potential Capital InefficiencyA rapidly expanding asset base without matching returns can signal capital inefficiency, tying up funds and depressing ROIC. Prolonged inefficiencies would lengthen payback periods on investments, reduce cash conversion, and pressure long-term return metrics unless addressed.
Poly Medicure Limited News
POLYMED FAQ
What was Poly Medicure Limited’s price range in the past 12 months?
Poly Medicure Limited lowest stock price was ₹1248.40 and its highest was ₹2936.70 in the past 12 months.
What is Poly Medicure Limited’s market cap?
Poly Medicure Limited’s market cap is ₹132.65B.
When is Poly Medicure Limited’s upcoming earnings report date?
Poly Medicure Limited’s upcoming earnings report date is May 26, 2026 which is in 93 days.
How were Poly Medicure Limited’s earnings last quarter?
Poly Medicure Limited released its earnings results on Feb 05, 2026. The company reported ₹7.7 earnings per share for the quarter, missing the consensus estimate of ₹9.5 by -₹1.8.
Is Poly Medicure Limited overvalued?
According to Wall Street analysts Poly Medicure Limited’s price is currently Overvalued.
Does Poly Medicure Limited pay dividends?
Poly Medicure Limited pays a Annually dividend of ₹3.5 which represents an annual dividend yield of 0.19%. See more information on Poly Medicure Limited dividends here
What is Poly Medicure Limited’s EPS estimate?
Poly Medicure Limited’s EPS estimate is 9.1.
How many shares outstanding does Poly Medicure Limited have?
Poly Medicure Limited has 101,359,490 shares outstanding.
What happened to Poly Medicure Limited’s price movement after its last earnings report?
Poly Medicure Limited reported an EPS of ₹7.7 in its last earnings report, missing expectations of ₹9.5. Following the earnings report the stock price went down -1.196%.
Which hedge fund is a major shareholder of Poly Medicure Limited?
Currently, no hedge funds are holding shares in IN:POLYMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poly Medicure Limited
Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. In addition, it offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. Further, it provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. The company was incorporated in 1995 and is based in New Delhi, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Eris Lifesciences Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―